A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

This study is looking for adults aged 18 to 74 years old who have moderate to severe eczema. To be considered, your eczema should cover at least 10% of your body, and you should have an eczema severity score (EASI) of 16 or higher, along with a doctor's assessment indicating your eczema is at least 'moderate'. You also need to have experienced significant itching, with a score of 4 or higher on a pain scale during the week before joining.

Crucially, you would only be suitable if your past treatments for eczema, such as creams or ointments, haven't worked well enough, or you couldn't tolerate them. Researchers also want to make sure participants are not pregnant or breastfeeding. If you're a woman who could become pregnant, you'd need to agree to use effective contraception. Similarly, men taking part would also need to use effective contraception.

There are also some reasons why you might not be able to join. For example, if you have certain infections like hepatitis B or C, HIV, or active tuberculosis, you wouldn't be eligible. Also, if you have other serious health conditions or are taking certain medicines that could interfere with the study results or put your health at risk, you might not be able to participate. The study doctor would review all your health information to make the final decision.

If you decide to take part in this study, you would first go through a screening process to make sure you meet all the requirements. If you're eligible, you would then be randomly assigned to one of several groups. Some groups will receive different doses of the new medicine, IMG-007, while others will receive a placebo (a dummy medicine).

Neither you nor the study team will know which treatment you are receiving – this is called a 'double-blind' study and helps ensure the results are unbiased. You will be asked to take the study medicine or placebo regularly for a period, and you'll have scheduled visits to the clinic over several months, for up to 48 weeks in total. During these visits, the study team will carry out various assessments, such as checking your eczema symptoms, asking about any side effects, and possibly taking blood samples. They will be closely monitoring your health and how you respond to the treatment throughout the study.